Shares of Doximity fell 23.3% in pre-open trading today following the company’s fiscal Q4 2026 earnings released after Wednesday’s close. The quarterly report showed adjusted EPS of $0.26, missing the consensus of $0.28 - a 7.14% negative surprise - while revenue of $145.4 million slightly exceeded expectations.
What spooked investors most was the company’s fiscal 2027 outlook. For the year ending March 31, 2027, Doximity guided revenue to $664 million to $676 million and projected adjusted EBITDA of $323 million to $335 million. At the midpoint those EBITDA figures sit below the fiscal 2026 level, signaling an expected step-down in profitability.
Management attributed part of the softness to the health care provider digital pharma advertising market, describing short-term demand as soft and noting limited visibility. Executives said the market environment is being shaped by elevated policy uncertainty and increased macroeconomic risk, and that they expect overall market growth to be modest - likely at or below 5%.
Operationally, Doximity reported adjusted EBITDA of $65.8 million for the quarter, a 6% decline year-over-year, while revenue rose 5% versus the prior year. For the coming first quarter, management guided revenue of $151 million to $152 million, trailing analyst estimates of $153.7 million.
Analysts reacted swiftly. Jefferies downgraded the stock from Buy to Hold and cut its price target from $51 to $19, citing low visibility into pharmaceutical advertising spend amid regulatory and macro uncertainty and noting that elevated AI investment spending limits near-term upside. Wells Fargo moved the rating from Overweight to Equal Weight and set a $18 target. KeyBanc shifted to Sector Weight, flagging that budget managers are seeking innovative AI and lower-cost solutions outside Doximity’s premium offerings.
The broader market offered no obvious justification for the selloff. The S&P 500 rose 0.58% and the Nasdaq gained 1.20% during the same session, indicating that the decline in Doximity’s stock was driven by company-specific news rather than a wider market downturn.
Management characterized the coming period as an "AI investment year," pointing to increased spending on AI compute. That heightened investment was cited as the main factor behind the projected compression of EBITDA margins, which the company expects to fall to roughly 49% for fiscal 2027. Investors who had grown accustomed to the company’s historically higher profitability reacted negatively to the prospect of a sustained margin step-down.
The market response also reflected fragile sentiment heading into the report. In the 90 days prior to the print, Doximity had recorded zero positive EPS revisions and 15 negative EPS revisions, suggesting that expectations were already weakening. The earnings miss, the downbeat EBITDA outlook, caution on the pharma ad market, and coordinated analyst downgrades combined to push the stock toward multi-year lows.
Doximity’s shares entered the session after a challenging run: the stock has fallen about 53% over the past six months and was trading 69% below its 52-week high of $76.51. It also traded well below its 52-week low of $20.55 following the wave of negative reactions to the release.
Summary
Doximity reported a fiscal Q4 EPS shortfall and provided a cautious fiscal 2027 guide that implies lower adjusted EBITDA and compressed margins as the company increases AI compute spending and faces softness in the digital pharma ad market. The combination of the earnings miss and simultaneous analyst downgrades produced a steep pre-market decline in the stock.
Key points
- Quarterly adjusted EPS of $0.26 missed the $0.28 consensus while revenue of $145.4 million modestly beat estimates.
- Fiscal 2027 guidance calls for revenue of $664 million to $676 million and adjusted EBITDA of $323 million to $335 million, implying lower margins - management projects about a 49% EBITDA margin for FY2027.
- Analyst firms including Jefferies, Wells Fargo, and KeyBanc downgraded ratings and slashed price targets, reflecting concerns about pharma advertising demand, regulatory and macro uncertainty, and elevated AI spending.
Risks and uncertainties
- Softness in the health care provider digital pharma advertising market may limit revenue growth and affect companies in health-tech and digital advertising sectors.
- Elevated investments in AI compute could continue to pressure EBITDA margins, creating profitability risk for tech and software firms that are increasing AI-related expenditures.
- Limited visibility due to regulatory and macroeconomic uncertainty could lead budget managers to delay or shift advertising and technology spend, impacting revenue visibility in the healthcare ad market.
Investors now face a reset in expectations for Doximity as the company balances increased AI investment with muted near-term demand in its core advertising market. The market reaction underscores how quickly sentiment can shift when guidance, profitability outlooks, and analyst views align against a stock.